Show simple item record

dc.contributor.authorNelson, AW
dc.contributor.authorGroen, AJ
dc.contributor.authorMiller, JL
dc.contributor.authorWarren, AY
dc.contributor.authorHolmes, KA
dc.contributor.authorTarulli, GA
dc.contributor.authorTilley, WD
dc.contributor.authorKatzenellenbogen, BS
dc.contributor.authorHawse, JR
dc.contributor.authorGnanapragasam, VJ
dc.contributor.authorCarroll, JS
dc.date.accessioned2020-12-21T03:45:39Z
dc.date.available2020-12-21T03:45:39Z
dc.date.issued2017-01-15
dc.identifierpii: S0303-7207(16)30485-3
dc.identifier.citationNelson, A. W., Groen, A. J., Miller, J. L., Warren, A. Y., Holmes, K. A., Tarulli, G. A., Tilley, W. D., Katzenellenbogen, B. S., Hawse, J. R., Gnanapragasam, V. J. & Carroll, J. S. (2017). Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 440 (C), pp.138-150. https://doi.org/10.1016/j.mce.2016.11.016.
dc.identifier.issn0303-7207
dc.identifier.urihttp://hdl.handle.net/11343/257340
dc.description.abstractEstrogen Receptor-β (ERβ) has been implicated in many cancers. In prostate and breast cancer its function is controversial, but genetic studies implicate a role in cancer progression. Much of the confusion around ERβ stems from antibodies that are inadequately validated, yet have become standard tools for deciphering its role. Using an ERβ-inducible cell system we assessed commonly utilized ERβ antibodies and show that one of the most commonly used antibodies, NCL-ER-BETA, is non-specific for ERβ. Other antibodies have limited ERβ specificity or are only specific in one experimental modality. ERβ is commonly studied in MCF-7 (breast) and LNCaP (prostate) cancer cell lines, but we found no ERβ expression in either, using validated antibodies and independent mass spectrometry-based approaches. Our findings question conclusions made about ERβ using the NCL-ER-BETA antibody, or LNCaP and MCF-7 cell lines. We describe robust reagents, which detect ERβ across multiple experimental approaches and in clinical samples.
dc.languageEnglish
dc.publisherELSEVIER IRELAND LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleComprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity
dc.typeJournal Article
dc.identifier.doi10.1016/j.mce.2016.11.016
melbourne.affiliation.departmentSchool of BioSciences
melbourne.source.titleMolecular and Cellular Endocrinology
melbourne.source.volume440
melbourne.source.issueC
melbourne.source.pages138-150
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1118222
melbourne.contributor.authorTarulli, Gerard
dc.identifier.eissn1872-8057
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record